Esperion Therapeutics Inc (ESPR NASDAQ) stock market data APIs
$2.2
0.12(5.8%)
as of January 23, 2025
Esperion Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Prev. Close
2.08
Open
2.2
Volume
6 605 K
High
2.26
Low
2.02
52 wk Range
1.58-3.94
Market Cap
433 M
Shares Outstanding
197 M
Revenue
295 M
EPS
-0.15
Beta
0.954
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Esperion Therapeutics Inc data using free add-ons & libraries
Get Esperion Therapeutics Inc Fundamental Data
Esperion Therapeutics Inc Fundamental data includes:
- Net Revenue: 295 M
- EBITDA: 16 497 K
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-11-05
- EPS/Forecast: -0.18
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Esperion Therapeutics Inc News
New
Is Esperion Therapeutics, Inc. (ESPR) the Best NASDAQ Stock Under $5?
We recently compiled a list of 7 Best NASDAQ Stocks Under $5. In this article, we will look at where Esperion Therapeutics, Inc. (NASDAQ:ESPR) ranks among the best NASDAQ stocks under $5. Job Market ...
3 Penny Stocks to Buy if You Want to Spend Less and Earn More
Investing in penny stocks can be a thrilling way to explore the potential for substantial gains. Despite their inherent risks, these stocks often appeal to adventurous investors looking to diversify t...
Heart Disease Drugmaker Esperion Therapeutics Reports Highest Revenue Yet, Stock Soars
Heart Disease Drugmaker Esperion Therapeutics Reports Highest Revenue Yet, Stock Soars Tuesday, Esperion Therapeutics (NASDAQ:ESPR) reported first-quarter revenues of $137.74 million, up 467% Y/Y, s...
11 Best Low Price Pharma Stocks To Invest In
In this piece, we will take a look at the 13 best low price pharma stocks to invest in. If you want to skip our overview of the pharma industry and want to skip to the five top low price stocks in thi...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
